Sunday, 18 October 2026

Follow on Google

diarioempresas

IBEX 3519.326,30▲ +0,77%EuroStoxx 506204,23▲ +0,58%S&P 5007659,44▼ -1,09%€/$1,1242▲ +0,19%Brent109,86▲ +3,72%Bitcoin72.951▲ +0,74%
Breaking
The BNG labels the Xunta's income tax cuts for 2027 as 'ridiculous'Almirall rises by 0.59% at the opening, trading at 10.26 eurosThe number of young self-employed workers in Extremadura rises by 14%Cádiz adds 99.6 MW of renewables in the first half and leads in wind powerNine Andalusian startups enter the Top 101 most innovative in Spain49% of large companies have not updated their AI governance
Markets

Almirall rises by 0.59% at the opening, trading at 10.26 euros

Almirall rises by 0.59% and trades at 10.26 euros at the opening, with a daily range of 10.20 to 10.26 euros and an average target price of 14.32 euros.

Daniel Ríos Company
Daniel Ríos Company
· 1 min read
AIIllustrative image: an amber glass jar on a light surface next to a window, with ample empty space around
Illustrative image: an amber glass jar on a light surface next to a window, with ample empty space around

Almirall's stock is trading at 10.26 euros at the start of the session, with a rise of 0.59%. The average one-year target price is 14.32 euros.

The stock of Almirall, S.A. (ALM.MC) is trading at 10.26 euros with the market already open, representing an increase of 0.06 euros, equivalent to 0.59%. This data, as of 9:01:30 (CEST), is included in information published by es.finance.yahoo.com.

The value opened at 10.22 euros, above the previous close of 10.20 euros. Its daily range is between 10.20 and 10.26 euros, with a volume of 3,455 shares compared to an average of 131,699.

In the last twelve months, the share price has fluctuated between 9.81 and 13.98 euros. The intraday market capitalisation is 2.233 billion and the price/earnings ratio is 31.09, with an EPS of 0.33 in the last year.

The company, based in Barcelona and founded in 1943, is dedicated to biopharmaceuticals focused on skin health. Among its R&D agreements are those with Evotec and Novo Nordisk.

The average one-year target price estimate is 14.32 euros. Key dates for investors are 14 May 2026, the ex-dividend date, and 9 November 2026, the expected date for results.

Daniel Ríos Company

Written by

Daniel Ríos Company

Redactor

Graduado en Economía por CUNEF y adicto a las pantallas en rojo y verde. Cafés dobles antes de la apertura, escéptico de los gurús y traductor del Ibex para mortales; en Diario Empresas firma los mercados.

You may also like